NCT05081180 2026-01-23
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
EMD Serono
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Recruiting
NCT00121719 2023-06-22
An Open Label Dose Escalation Study Of E7080
Eisai Inc.
Phase 1 Completed
NCT01268293 2023-06-22
A Study of E7080 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00280397 2016-10-07
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00121680 2015-12-11
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Eisai Inc.
Phase 1 Completed
NCT01240408 2015-03-04
E7080 Food Effect Study in Healthy Subjects
Eisai Inc.
Phase 1 Completed